Trial Information

Summary: Study comparing Anastrozole vs. anastrozole and fulvestrant for post-menopausal women with metastic breast cancer.

The Dyson Center for Cancer Care at Vassar Brothers Medical Center in conjunction with the National Cancer Institute (NCI) and Southwest Oncology Group (SWOG) is conducting the SWOG – S0226 Research Protocol.

This is a Phase III randomized trial of Anastrozole vs. Anastrozole and Fulvestrant as first line therapy for post-menopausal women with metastatic breast cancer.

Endocrine therapy plays a central role in the treatment of metastatic breast cancer. Essentially all patients with metastatic disease eventually develop resistance to these agents, the goal of endocrine therapy in breast cancer is palliative. The most widely used endocrine therapy over the last two decades has been tamoxifen. Over the last decade new agents have been developed including the aromatase inhibitor, anastrozole, and the pure anti-estrogen, fluvestrant. The important question in clinical trials is if the combinations of these new agents might have advantages over the use of single agents.

Eligibility criteria:

• Metastatic breast cancer.
• Postmenopausal.
• Positive hormonal assay of tumor.
• Prior chemotherapy/hormone therapy/immunotherapy for recurrent or metastatic disease are not eligible.

If you are interested in this study please feel free to check with the Clinical Research Department at Vassar Brothers Medical Center for additional eligibility/ineligibility criteria.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.